TY - JOUR
T1 - American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update
AU - Camacho, Pauline M.
AU - Petak, Steven M.
AU - Binkley, Neil
AU - Diab, Dima L.
AU - Eldeiry, Leslie S.
AU - Farooki, Azeez
AU - Harris, Steven T.
AU - Hurley, Daniel L.
AU - Kelly, Jennifer
AU - Michael Lewiecki, E.
AU - Pessah-Pollack, Rachel
AU - McClung, Michael
AU - Wimalawansa, Sunil J.
AU - Watts, Nelson B.
N1 - Funding Information:
Principal Investigator, research grant support.
Funding Information:
Neil Binkley, MD: Amgen, consultant; Radius Health, GE Healthcare, research grant support.
Publisher Copyright:
© 2020 AACE.
PY - 2020/5/15
Y1 - 2020/5/15
N2 - Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). Methods: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols. Results: The Executive Summary of this 2020 updated guideline contains 52 recommendations: 21 Grade A (40%), 24 Grade B (46%), 7 Grade C (14%), and no Grade D (0%). These detailed, evidence-based recommendations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world care of patients. The evidence base presented in the subsequent Appendix provides relevant supporting information for the Executive Summary recommendations. This update contains 368 citations: 123 (33.5%) evidence level (EL) 1 (highest), 132 (36%) EL 2 (intermediate), 20 (5.5%) EL 3 (weak), and 93 (25%) EL 4 (lowest). New or updated topics in this CPG include: clarifcation of the diagnosis of osteoporosis, stratifcation of the patient according to high-risk and veryhigh-risk features, a new dual-action therapy option, and transitions from therapeutic options. Conclusion: This guideline is a practical tool for endocrinologists, physicians in general, regulatory bodies, health-related organizations, and interested laypersons regarding the diagnosis, evaluation, and treatment of postmenopausal osteoporosis.
AB - Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). Methods: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols. Results: The Executive Summary of this 2020 updated guideline contains 52 recommendations: 21 Grade A (40%), 24 Grade B (46%), 7 Grade C (14%), and no Grade D (0%). These detailed, evidence-based recommendations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world care of patients. The evidence base presented in the subsequent Appendix provides relevant supporting information for the Executive Summary recommendations. This update contains 368 citations: 123 (33.5%) evidence level (EL) 1 (highest), 132 (36%) EL 2 (intermediate), 20 (5.5%) EL 3 (weak), and 93 (25%) EL 4 (lowest). New or updated topics in this CPG include: clarifcation of the diagnosis of osteoporosis, stratifcation of the patient according to high-risk and veryhigh-risk features, a new dual-action therapy option, and transitions from therapeutic options. Conclusion: This guideline is a practical tool for endocrinologists, physicians in general, regulatory bodies, health-related organizations, and interested laypersons regarding the diagnosis, evaluation, and treatment of postmenopausal osteoporosis.
UR - http://www.scopus.com/inward/record.url?scp=85084965106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084965106&partnerID=8YFLogxK
U2 - 10.4158/GL-2020-0524SUPPL
DO - 10.4158/GL-2020-0524SUPPL
M3 - Review article
C2 - 32339028
AN - SCOPUS:85084965106
SN - 1530-891X
VL - 26
SP - 1
EP - 46
JO - Endocrine Practice
JF - Endocrine Practice
IS - s1
ER -